Last Updated : January 15, 2019
Details
FilesProject Status:
Completed
Project Line:
Health Technology Review
Project Sub Line:
Optimal Use
Project Number:
OP0538-000 / CT0001
Final Biosimilar Summary Dossier Issued:
Tisagenlecleucel is a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and children and young adults with relapsed or refractory acute lymphoblastic leukemia.
CADTH undertook a review of manufacturer-submitted materials and published literature to assess the clinical impact, cost-effectiveness, and implementation considerations, including patient and caregiver perspectives and experiences, ethical considerations, and other considerations, such as facilities for the administration of CAR T-cell therapy, therapy eligibility, travel requirements, and resource costs associated with the provision of tisagenlecleucel therapy in Canada.
The project has following key components:
- protocols
- clinical systematic review
- economic review
- review of implementation considerations, ethics, and patient and caregiver perspectives and experiences
- recommendations report.
Read more about CAR T-cell therapy reviews at CADTH.
Files
Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma
Optimal Use
In Brief
PUBLISHED: January 15, 2019
Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-cell Lymphoma: Recommendations
Optimal Use
Recommendation Report
PUBLISHED: January 15, 2019
Tisagenlecleucel for Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma: Clinical Report
Optimal Use
Clinical Report
PUBLISHED: January 15, 2019
Optimal Use
Ethics and Implementation Report
PUBLISHED: January 15, 2019
Tisagenlecleucel for Diffuse Large B-Cell Lymphoma: Economic Review Report
Optimal Use
Economic Review Report - DLBCL
PUBLISHED: January 15, 2019
Tisagenlecleucel for Acute Lymphoblastic Leukemia: Economic Review Report
Optimal Use
Economic Review Report - ALL
PUBLISHED: January 15, 2019
Optimal Use
Project Protocol, Clinical Section
Volume 8, Issue 3a
PUBLISHED: September 6, 2018
Optimal Use
Project Protocol, Implementation and Ethics Section
Volume 8, Issue 3b
PUBLISHED: September 21, 2018
Optimal Use
Patient Input Submissions
PUBLISHED: December 11, 2018
Files
Last Updated : January 15, 2019